Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
Аннотация
Objectives We aimed to estimate whether adding oral glucocorticoids to ILD‐modifying therapy improves 12‐month lung outcomes in systemic sclerosis‐associated interstitial lung disease (SSc‐ILD). Methods We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc‐ILD initiated an eligible ILD‐modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone‐equivalent dose ≤20 mg/day). Follow‐up ended at the visit closest to 12 months within a 9 to 15‐month window. The primary outcome was the between‐group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules. Results Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD‐modifying therapy and 258 (58.2%) received ILD‐modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12‐month FVC. The adjusted mean difference in FVC change was ‐2.10 percentage points (95% CI ‐4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated‐weight sensitivity analysis. Conclusion Adding oral glucocorticoids to ILD‐modifying therapy was not associated with improved 12‐month FVC in SSc‐ILD. Secondary outcomes were sparse and should be interpreted cautiously. image